Sign Up Today and Learn More About Biosplice Therapeutics Stock
Invest in or calculate the value of your shares in Biosplice Therapeutics or other pre-IPO companies through EquityZen's platform.
Biosplice Therapeutics Stock (BITH)
Biosplice Therapeutics is in the medical research and development for tissue-level regeneration.
About Biosplice Therapeutics Stock
Founded
2008
Headquarters
San Diego, CA, US
Total Funding
658M
Industries
Software, Artificial Intelligence, Data and Analytics
Biosplice Therapeutics Press Mentions
Stay in the know about the latest news on Biosplice Therapeutics
4-aminopyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof
patents • May 04, 2025
4-ALCOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND THEIR PREPARATION AND USE
patents • May 04, 2025
Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway …
patents • May 04, 2025
Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof
patents • Feb 12, 2025
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
patents • Feb 12, 2025
Investors in Biosplice Therapeutics
Discover investors in Biosplice Therapeutics stock and explore their portfolio companies
Biosplice Therapeutics Management
Leadership team at Biosplice Therapeutics
Executive Chairman & Founder
Osman Kibar
Chief Medical Officer
Yusuf Yazici
Join now and verify your accreditation status to gain access to:
- Biosplice Therapeutics Current Valuation
- Biosplice Therapeutics Stock Price
- Biosplice Therapeutics Management
- Available deals in Biosplice Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Biosplice Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Biosplice Therapeutics Revenue and Financials
- Biosplice Therapeutics Highlights
- Biosplice Therapeutics Business Model
- Biosplice Therapeutics Risk Factors
- Biosplice Therapeutics Research Report from SACRA Research
Trading Biosplice Therapeutics Stock
How to invest in Biosplice Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Biosplice Therapeutics through EquityZen funds. These investments are made available by existing Biosplice Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Biosplice Therapeutics stock?
Shareholders can sell their Biosplice Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
